Mangalam Drugs Peer Comparison

NSE: MANGALAM | BSE: 532637

₹28.65

₹-0.92 (-3.11%)

As on 23-Oct-2026IST

Market cap

₹44 Cr

Revenue (TTM)

₹232 Cr

P/E Ratio

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	44	29,269	25,696	25,409	23,588
Revenue (₹ Cr)	232	3,564	1,462	9,205	1,936
Net Profit (₹ Cr)	-38.24	414.00	387.35	-371.81	288.22
Net Margin (%)	-16.43	11.23	26.01	-3.93	14.79
RoE (%)	-33.16	8.38	25.18	-3.85	29.77
Price to Earnings	--	71.56	66.53	--	81.84
Price-To-Book	0.50	5.81	14.89	3.17	17.57

Income Statement (₹ Cr)

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	232.44	3,564.00	1,461.80	9,205.28	1,935.80
Total Income	232.78	3,686.00	1,489.25	9,449.59	1,948.58
Total Expenditure	241.21	2,792.00	919.25	8,195.15	1,485.56
EBITDA	-8.77	772.00	542.56	1,010.13	450.24
Depreciation	17.45	226.00	37.68	857.51	50.83
EBIT	-26.22	546.00	504.88	152.62	399.41
Interest	15.84	217.00	3.77	342.73	40.84
Other Income	0.34	122.00	27.45	244.31	12.78
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	-41.72	463.00	528.56	-162.68	371.35
Provision for Tax	-4.08	49.00	141.21	209.13	83.14
Profit after Tax	-37.64	414.00	387.35	-371.81	288.22

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	103.32	4,940.00	1,653.56	8,162.62	1,288.82
Minority Interest	0.00	-5.00	-1.13	0.00	0.00
Non-Current Liabilities	15.33	1,712.00	42.40	5,044.14	202.03
Current Liabilities	189.49	1,622.00	230.82	4,758.28	835.87
Total Liabilities	--	8,578.00	1,983.96	17,723.32	2,326.71

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	141.86	5,343.00	1,026.85	10,211.52	519.60
Current Assets	155.69	2,606.00	881.27	7,191.66	1,681.81
Total Assets	--	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	--	2,125.00	26.49	5,495.48	259.37
Net Current Assets	-33.80	984.00	650.46	2,433.38	845.94
Contingent Liabilities	--	768.26	17.25	95.72	19.09

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	--	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	--	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	--	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	--	95.00	30.33	787.59	78.39

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	--	6.79	32.42	1.24	29.22
ROE (%)	-32.62	8.38	25.18	-3.85	29.77
ROA (%)	-11.28	4.94	21.93	-2.21	24.77
EBIT Margin (%)	-11.28	15.32	34.54	1.66	20.63
Net Margin (%)	-16.17	11.23	26.01	-3.93	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	-22.17	18.37	40.90	0.78	46.65
EBIT Growth (%)	-549.97	252.26	124.50	-70.53	62.13
Net Profit Growth (%)	-296.70	377.85	104.15	-1,383.43	89.49
EPS Growth (%)	-296.70	1,001.33	42.32	-484.84	78.60
Book Value Growth (%)	--	13.47	26.03	0.33	144.31

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	-1.18	73.45	66.53	-81.20	80.58
Price / Book Value	0.46	5.81	14.89	3.17	17.57
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.11
EV/EBITDA	-17.45	39.81	46.99	29.25	52.20
Market Cap (₹ Cr)	--	19,071.62	20,944.75	18,108.89	12,753.19

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.07	0.31	0.02	0.53	0.11
Short term debt to equity ratio	--	0.09	0.02	0.09	0.05
Current Ratio	0.82	1.61	3.82	1.51	2.01
Quick Ratio	0.28	1.06	2.82	0.87	1.14
Interest Coverage	-1.63	3.13	141.16	0.53	10.09

	Mangalam Drugs	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	17.34	16.50	24.80	23.44	26.28
Asset Turnover	0.70	0.43	0.83	0.55	1.66
Receivable days	--	58.75	88.98	78.20	40.13
Inventory Days	--	75.82	56.04	93.30	60.29
Payable days	--	186.21	99.95	226.14	232.47
Cash Conversion Cycle	--	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.